Cofactor Genomics joins FNIH Biomarkers Consortium

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cofactor Genomics said it has become a member of the Foundation for NIH Biomarkers Consortium with the goal of advancing the adoption of multidimensional biomarkers in cancer and immune-related diseases.

Formally launched in 2006, the FNIH Biomarkers Consortium is a major public-private biomedical research partnership managed by the FNIH with broad participation from stakeholders across biomedical research, including government, industry, academia, patient advocacy, and other not-for-profit organizations.

In addition to the FNIH, founding members include NIH, FDA, the Pharmaceutical Research and Manufacturers of America, the Centers for Medicare & Medicaid Services, and BIO.

The FNIH Biomarkers Consortium brings together expertise and resources of various partners to rapidly identify, develop, and seek qualification of potential high-impact biomarkers particularly to enable improvements in drug development, clinical care, and regulatory decision-making.

Cofactor’s success in demonstrating the utility of Predictive Immune Modeling with their ImmunoPrism assay positions them to add value to a number of the initiatives of the FNIH Biomarkers Consortium, specifically in the area of inflammation, immunity, and cancer.

Cofactor’s technical teams will participate in the FNIH Biomarkers Consortium and offer expertise in ImmunoPrism reagents and services to achieve advanced profiling of immune response.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login